Abstract

Targeting glycolysis in cancer therapy has emerged as a promising strategy due to the unique metabolic adaptations of tumor cells. This paper explores current and innovative approaches to inhibiting glycolysis, focusing on key glycolytic enzymes, glucose transporters, and combination therapies. It also examines novel targets, metabolic reprogramming strategies, and advanced drug delivery systems using nanotechnology. Despite the promise of these approaches, challenges such as resistance, toxicity, and ethical considerations remain. Personalized medicine and continued research are crucial for overcoming these obstacles and improving patient outcomes. Collaborative efforts are needed to translate these findings into effective clinical treatments.